FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT O

F CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>STACK DAVID M</u>							2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN]								ionship of Reporting all applicable) Director		10% Ov	vner	
(Last) (First) (Middle) C/O AMARIN PHARMA, INC. 1430 ROUTE 206						3. Date of Earliest Transaction (Month/Day/Year) 05/17/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)								Office below	er (give title v)		Other (s below)	pecify	
														6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BEDMINSTER NJ 07921															X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	City) (State) (Zip)																		
		Ta	ble I - N	lon-De	rivativ	/e Se	curiti	es Ac	quire	ed, Di	isposed of	f, or Be	neficial	ly Owne	d				
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/						Exe r) if a	ny	ution Date,		action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Secur Benef Owne	cially I Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Trans	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Ordinary Shares ⁽¹⁾⁽²⁾ 05/17/20						19		М		13,174	Α	\$3.21	13	13,174 ⁽³⁾		D			
Ordinary Shares ⁽¹⁾⁽²⁾ 05/17/20						19		S		13,174	D	\$18.000	5(4)	0(3)		D			
			Table I							,	posed of, convertib		•	Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exe Expiration I (Month/Day		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	e derivativ Securitie Beneficia Owned Following Reported	e es ally g i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
						v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	Amount or Number of Shares	1	Transact (Instr. 4)	ion(s)	<u> </u>		
Stock Option (Right to Buy)	\$3.21	05/17/2019			М			13,174	4 (5)		05/14/2028	Ordinar Shares ⁽²		\$0.00	33,79	33,799			
Stock Option (Right to Buy)	\$16.83	05/20/2019					9,658		(6)		05/20/2029	Ordinar Shares ⁽²		\$0.00	9,65	8	D		
Restricted Stock Units	\$0.00 ⁽⁷⁾	05/20/2019			A		7,428			(8)	(9)	Ordinar Shares ⁽²		\$0.00	7,42	8	D		

Explanation of Responses:

- 1. The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 3. Please see the section titled "Remarks" below for additional information.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. The stock option granted to the Reporting Person is fully vested as of the date hereof.
- 6. On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020.
- 7. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
- 8. On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year.
- 9. Not applicable.

Remarks:

In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. This number does not represent the aggregate number of Ordinary Shares of the Issuer this Reporting Person holds or has a right to acquire in the form of stock options and restricted stock units granted to such Reporting Person. The grants made on May 20, 2019 are made in accordance with the Issuer's previously disclosed non-employee director compensation program.

> /s/ Joseph Kennedy, by power of attorney

05/21/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.